NEW YORK, January 1, 2026, 15:38 ET — Market closed
- AbbVie shares last closed down 0.5% at $228.49 on Wednesday. 1
- Wall Street ended 2025’s final session lower in thin holiday trading. 2
- Attention turns to the Fed’s late-January meeting and AbbVie’s mid-January dividend record date. 3
AbbVie Inc. shares last closed down 0.5% at $228.49 on Wednesday, the final U.S. trading session of 2025, with Wall Street closed on Thursday for the New Year’s Day holiday. 2
The market closure matters because AbbVie and other large-cap drugmakers often act as a defensive trade when investors reassess risk at the start of a new year. With liquidity returning in the next session, traders will be watching whether late-December selling pressure persists. 2
U.S. stocks ended lower on Wednesday, with the S&P 500 down 0.74%, the Nasdaq off 0.76% and the Dow down 0.63%, Reuters reported. 2
“It’s perfectly fine in any bull market to have moments of cost,” said Giuseppe Sette, co-founder and president of Reflexivity, pointing to profit-taking in low-liquidity conditions. 2
AbbVie traded between $228.43 and $230.25 in Wednesday’s session after opening at $229.74, according to the company’s investor relations stock-quote page. 1
The stock sits about 6.7% below its 52-week high of $244.81 and roughly 39% above its 52-week low of $164.39, levels technicians often use as near-term resistance and support markers. 1
Chart watchers also note AbbVie is above its 50-day moving average of about $226.70 and its 200-day moving average near $205.99, according to Yahoo Finance statistics. 4
The drugmaker has been working to offset the decline of former blockbuster Humira after it began facing U.S. biosimilar competition, leaning on newer immunology medicines such as Skyrizi and Rinvoq. 5
Income-focused investors have another near-term catalyst: AbbVie’s board last announced a quarterly dividend of $1.74 per share payable Feb. 17, 2026, to shareholders of record on Jan. 16, 2026. 6
Peer moves were mixed in the last session. Johnson & Johnson was little changed, while Merck and Pfizer fell and Eli Lilly dipped, as the healthcare sector also softened.
Before the next session, investors will gauge whether the market’s year-end slide extends into early 2026 after Wall Street finished the final trading day lower in holiday-thinned conditions. 2
Macro focus is also building ahead of the Federal Reserve’s Jan. 27–28 policy meeting; investors currently expect the central bank to leave rates unchanged, Reuters reported earlier this week. 3
For AbbVie specifically, traders will watch whether shares hold above the mid-$220s area around the 50-day average and stay within striking distance of the $244.81 52-week high, while awaiting the company’s next earnings update and any guidance on the post-Humira transition. 1
